Halozyme Therapeutics
HALO • NASDAQ
Halozyme Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Helen I. Torley, with a market cap of $7.9B.
Market Cap$7.9B
Employees373.0
CEOHelen I. Torley
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 5, 2026 · In 3 weeksQ1 2026
Financials
Halozyme Therapeutics FAQ
Common questions about Halozyme Therapeutics
Halozyme Therapeutics is scheduled to report earnings for Q1 2026 on May 5, 2026. Analysts estimate revenue of $358.1M.
Halozyme Therapeutics has approximately 373 employees.